NCT04038034Unknown不适用
Clinical Evaluation of the Antioxidant and Neuroprotective Effects of CoQ10-MINIACTIVES® (COQUN® OS) 100 mg BID Oral Administration in Patients Affected by Primary Open Angle Glaucoma (POAG): a Randomized, Double Blind Study
适应症
干预措施
试验速览
- 阶段
- 不适用
- 入组人数
- 70
- 试验地点
- 2
- 主要终点
- Pattern Electroretinogram Amplitude (PERG P50-N95 A)
研究概览
简要总结
This is a randomized, double blind study with competitive enrolment, aimed to enroll a total of 70 patients with a diagnosis of primary open angle glaucoma (POAG).
Patients, after signing the Informed Consent, will enter into a 1- week screening phase during which the baseline tests will be conducted.
Subjects will be randomized in a 1:1 ratio to the following groups:
- group A of 35 patients treated with pressure lowering drugs and placebo;
- group B of 35 patients with pressure lowering drugs and COQUN oral formulation 100 mg BID.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 40 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient Informed consent form (ICF) signed
- •M & F Aged ≥ 40 and ≤ 80 years at the time of the signature of ICF
- •Patients with Primary Open Angle Glaucoma (POAG) stage early-moderate according to Hodapp-Parrish-Anderson criteria (MD less than -12 dB)
- •Patients must be diagnosed with POAG at least 1 year before the screening visit in this study.
- •Anamnesis with at least 1 value of Intraocular pressure (IOP) >21mmHg documented any time prior the initiation of the stable treatment with anti-hypertensive topical drugs.
- •Patients affected by POAG and under stable treatment with anti-hypertensive topical drugs in the previous 6 months prior to enrolment to maintain IOP ≤18 mmHg.
- •Corrected visual acuity (using ETDRS tables) ≥ 8/10
- •Transparent dioptric means to allow the examination of the OCT >25 μm.
- •Pachymetry values between 500 and 600 μm.
- •Patients have to show a stable visual field in the previous 6 months prior to enrolment (where by stable visual field it is intended that the patient must remain within the same stage of POAG severity (i.e. early or moderate) during the previous 6 months before the enrolment).
- •Willing to follow all study procedures, including attending all site visits, tests and examinations.
- •Women must agree to be using two forms of effective contraception, be post-menopausal from at least 12 months prior to trial entry, or surgically sterile.
排除标准
- •Patients with a severe defect of POAG according to Hodapp-Parrish-Anderson criteria.
- •Previously diagnosed optic neuropathies.
- •Diabetic retinopathy or Hypertensive retinopathy.
- •Decompensated diabetes.
- •Not stabilized hypertension (SAP and/or DAP) despite under adequate pharmacological treatment.
- •Retinal pathologies including hereditary forms.
- •Neurological, neurodegenerative or cerebrovascular conditions.
- •No previous history or presence of any disease involving cornea or retina.
- •Patients with a significantly progressive opacity of lens in the previous 3 months prior to enrolment (where by significant progressive opacity of lens it is intended patients who have been diagnosed with cataracts of any aetiology and for whom surgery is being considered).
- •No surgical intervention for cataract in the previous 3 months prior to enrolment.
- •Eye inflammatory conditions (uveitis) diagnosed any time in the patient's history.
- •Treatment with topical or systemic neuroprotective agents different from CoQ
- •These patients can be admitted in the study after at least a 1 month of wash-out period.
- •Treatment with warfarin.
- •Treatment with miotic drugs able to influence the visual field.
- •Treatment with systemic or topical steroids.
- •Refractive defects beyond the 5 spherical diopters, both positive and negative and over 3 cylindrical.
- •Any clinically significant history of serious digestive tract, liver, kidney, cardiovascular, cancer or hematological disease.
- •Known drug and/or alcohol abuse.
- •Mental incapacity that precludes adequate understanding or cooperation.
- •Participation in another investigational study or blood donation within 3 months prior to ICF signature.
研究组 & 干预措施
group A
Placebo Comparator
35 patients treated with pressure lowering drugs and placebo
干预措施: Placebo (Dietary Supplement)
group B
Experimental
35 patients with pressure lowering drugs and COQUN oral formulation 100 mg BID.
干预措施: CoQ10- MINIACTIVES (Dietary Supplement)
结局指标
主要结局
Pattern Electroretinogram Amplitude (PERG P50-N95 A)
时间窗: between the baseline visit (V0) and the last study visit after 12 months of treatment (V3)
To evaluate the difference of mean changes of Pattern Electroretinogram Amplitude (PERG P50-N95 A) (μV) observed between the two study groups.
次要结局
- Optical Coherence Tomography(between the baseline visit (V0) and Month 4 and Month 8 and the last study visit after 12 months of treatment (V3))
- Visual Evoked Potentials Implicit Times (VEP P100 IT)(between the baseline visit (V0) and Month 4 and Month 8 and the last study visit after 12 months of treatment (V3))
- Pattern Electroretinogram Amplitude (PERG P50-N95 A)(between the baseline visit (V0) and Month 4 and Month 8 and the last study visit after 12 months of treatment (V3))
- Visual Evoked Potentials Amplitude (VEP N75-P100 A)(between the baseline visit (V0) and Month 4 and Month 8 and the last study visit after 12 months of treatment (V3))
- Visual field(from baseline to each study visit (V1, V2, V3))
- Contrast sensitivity(between the baseline visit (V0) and Month 4 and Month 8 and the last study visit after 12 months of treatment (V3))
- Pattern Electroretinogram Amplitude Implicit Times (PERG P50 IT)(between the baseline visit (V0) and Month 4 and Month 8 and the last study visit after 12 months of treatment (V3))
研究者
研究点 (2)
Loading locations...
相似试验
尚未招募
3 期
Clinical Trial to Investigate the Efficacy and Safety of Ondansetron (Danset - Adwia) Versus Placebo Plus the Standard of Care in the Treatment of Nausea and Vomiting in Adult Patients With Acute GastroenteritisGastroenteritisNCT05876585Genuine Research Center, Egypt126
已完成
3 期
A Clinical Trial to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and OverTetanusNCT06120751CanSino Biologics Inc.1,000
已完成
1 期
A Clinical Study to Investigate How Safe and Tolerable the Study Drug MT-2990 is and How MT-2990 is Taken up by the Body in Healthy VolunteersHealthyNCT03156738Mitsubishi Tanabe Pharma Corporation40
已完成
1 期
A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 DiabetesType 2 Diabetes MellitusNCT01474083vTv Therapeutics248
已完成
1 期
Clinical Trial to Assess Pharmacodynamic Effects on Segmental Endotoxin Induced Inflammatory Response of BI 1026706 Versus PlaceboHealthyNCT02657408Boehringer Ingelheim57